Penghambat CDK4/6 untuk Terapi Kanker Payudara

Hastarita Lawrenti


Terapi endokrin masih menjadi terapi utama kanker payudara reseptor estrogen positif; tetapi sampai dengan 50% pasien akan mengalami kekambuhan yang umumnya dikenal dengan resistensi didapat. Salah satu terapi untuk mengatasi resistensi tersebut adalah penghambat CDK4/6. Penghambat CDK4/6 dalam kombinasi dengan terapi endokrin tidak hanya efektif untuk pasien kanker payudara reseptor hormon positif, HER2 negatif yang progresif setelah terapi endokrin, tetapi juga untuk terapi awal berbasis endokrin.


Endocrine therapy is the mainstay treatment for patients with estrogen receptor positive breast cancer, however up to 50% patients will eventually experience relapse, known as acquired resistance. One of the treatment options to overcome resistance is CDK4/6 inhibitor. CDK4/6 inhibitor, in combination with endocrine therapy, is not only effective for patients with hormone receptor positive, HER2-negative breast cancer after progression with previous endocrine therapy, but also for initial endocrine-based therapy.

Full Text:



Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev. 2019;5:66.

Harbeck N, Gnant M. Breast cancer. Lancet 2017;389:1134-50.

Indonesia. Globocan 2020 [Internet]. 2021 [cited 2022 Feb 25]. Available from:

Krauss K, Stickeler E. Endocrine therapy in early breast cancer. Breast Care 2020;15:337-46.

Giuliano M, Schiff R, Osborne CK, Trivedi MV. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. The Breast 2011;20:S3,S42-9.

Dixon JM. Endocrine resistance in breast cancer. New Journal of Science 2014 doi: 10.1155/2014/390618.

Nagaraj G, Ma C. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2015 doi: 10.1007/s10549-015-3316-4.

Hartkopf AD, Grischke EM, Brucker SY. Endocrine-resistant breast cancer: Mechanisms and treatment. Breast Care 2020;15:347-54.

Haque MM, Desai KV. Pathways to endocrine therapy resistance in breast cancer. Front Endokrinol. 2019;10:573.

Fribbens C, O’Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961-8.

McAndrew NP, McCann KE. Why CDK 4/6 inhibitors are practice changing in advanced breast cancer? Oncology & Hematology Review (US) 2020;16(1):23-9.

Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, et al. CDK4/6 inhibitors in the treatemtn of patients with breast cancer: Summary of a multidisciplinary round-table discussion. ESMO Open 2019;3:e000368.

Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treatment Reviews 2016;45:129-38.

Niu Y, Xu J, Sun T. Cyclin-dependent kinases 4/6 inhibitors in breast cancer: Current status, resistance, and combination strategies. Journal of Cancer 2019;10(22):5504-17.

Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: Current practice and future directions. Ther Adv Med Oncol. 2018;10:1-15.

Kim ES, Scott LJ. Palbociclib: A review in HR-positive, HER2-negative advanced or metastatic breast cancer. Targ Oncol. 2017;12:373-83.

Ettl J. Palbociclib: First CDK4/6 inhibitor in clinical practice for the treatment of advanced HR-positive breast cancer. Breast Care 2016;11:174-6.

Palbociclib. Product Information. Available from:

Hui R, de Boer R, Lim E, Yeo B, Lynch J. CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care. Asia Pac J Clin Oncol. 2021;17(suppl. 1):3-14.

Shah M, Nunes MR, Stearns V. CDK4/6 inhibitors: Game changers in the management of hormone receptor-positive advanced breast cancer? Oncology (Williston Park) 2018;32(5):216-22.

Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 inhibitors in breast cancer: Current controversies and future directions. Curr Oncol Rep. 2019;21(3):25.

Spring L, Bardia A. Cycling toward progress: Ribociclib, a CDK 4/6 inhibitor for breast cancer. Clin Cancer Res. 2018 doi: 10.1158/1078-0432.CCR-18-0463.

Burris III HA. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Exp Rev Anticancer Ther 2018;18(3):201-13.

Shah A, Bloomquist E, Tang S, Fu W, Bi Y, Liu Q, et al. FDA approval: Ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Clin Cancer Res. 2018 doi: 10.1158/1078-0432.CCR-17-2369.

Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer. Breast Care 2016;11:167-73.

Ribociclib. Product Information. Available from:

Yardley DA. MONALEESA clinical program: A review of ribociclib use in different clinical settings. Future Oncol. 2019;15(23):2673-86.

Corona SP, Generali D. Abemaciclib: A CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Design, Development and Therapy 2018;12:321-30.

Abemaciclib. Product Information. Available from:

Kotake T, Toi M. Abemaciclib for the treatment of breast cancer. Expert Opinion on Pharmacotherapy 2018 doi: 10.1080.14656566.2018.1448787.

Chong QY, Kok ZH, Bui NLC, Xiang X, Wong ALA, Yong WP, et al. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib. Pharmacol Res. 2020 doi: 10.1016/j.phrs.2020.104686.

Anders CK, Le Rhun E, Bachelot TD, Yardley DA, Awada A, Conte PF, et al. A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC). J Clin Oncol. 2019;37(15 Suppl):1017.

Martin M, Garcia-Saenz JA, Manso L, Llombart A, Cassinello A, Atienza M, et al. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. Future Oncol. 2020 doi: 10.221/fon-2020-0604.


  • There are currently no refbacks.